This study highlights HMGB1 as a key regulator of esophageal cancer radioresistance, acting via the PI3K/AKT/ATM axis, and suggests that its inhibition could improve radiotherapy outcomes through enhanced cell death and impaired invasion. Here, AKT1 is linked to esophageal cancer.